Forbes is as corrupt as everyone else. Have you noticed that there is hardly any "news" anymore? It's all agenda propaganda for personal gain.
Afrezza is prandial insulin and that market is clearly not the whole world of diabetics. It's prescribing and use for pre-diabetics is yet to be resolved and needles aren't going away any time soon. Let's start from there, shall we?
You make it sound like Babcock is in the driver's seat and turning away offers. There are no offers. The medical community already knows the benefits of Cs-131, but more importantly, they know that ISR isn't selling its own product and struggles to make a profit on sales to begin with. If a big competitor isn't "an investor," why are you?
Why is it that dimwitted bashers have dimwitted aliases? It's almost an advertisement that lets you know what's coming even before you look at the comment. Ingenious.
You take the reading comprehension course. Your post lists more than one trial result. Nice copy and paste job, stox.
You're buying into Cramer's "schtick." He's a manipulator. The average person accepts it as unbiased when in fact he is just working the audience psychologically to achieve a personal goal.
"Adjuvant intraoperative brachytherapy has previously been reported to decrease LR to rates normally associated with lobectomy. Despite initial enthusiasm for adjuvant brachytherapy, we found no difference in outcome between patients treated with or without
brachytherapy. The theoretical benefit of brachytherapy is presumably provided through extending the therapeutic margin after resection. Therefore, the benefit of brachytherapy may only be in those few patients with compromised margins.
"In conclusion, this randomized prospective study demonstrates no advantage in local control when using adjuvant intraoperative brachytherapy in high-risk operable patients with stage I NSCLC of 3 cm. This negative finding may have been related to closer attention
to parenchymal margins by surgeons participating in this study."
You apparently haven't read the JCO Alliance Trial. Adjuvant brachytherapy is already deemed impotent for NSC lung cancer. Google: ACOSOG Z4032 (Alliance)
Sounds like you're reinforcing the theory that cancer may be treated in part by nutrients. Good for you. There's a lot of potential there.
Wasn't bashing. Just one more interesting outcome endorsed and funded by NCI. This kind of stuff is what we'll be seeing a lot more of in the future along with gene therapy.
Researchers at the University of Miami have found that an over-the-counter supplement is effective in both preventing and treating prostate cancer.
The supplement, 4-methylumbelliferone (4-MU), is a non-toxic oral agent used as a dietary supplement in Europe and Asia for improving liver health. Treating mice with the supplement appeared to inhibit prostate cancer from further developing starting as soon as eight weeks after the rodents were diagnosed.
“The results were simply amazing,” principal investigator Vinata B. Lokeshwar, a professor of urology and director of the pilot and translational studies component of the Miami Clinical and Translational Science Institute, said in a news release. The team also found that 4-MU halted the metastatic spread of prostate cancer.
According to the National Cancer Institute, prostate cancer is the most common nonskin cancer and second leading cause of cancer-related death in men in the U.S. In 2014, there were an estimated 233,000 new cases and about 30,000 deaths. Projections for 2015 are similar.
For their study, researchers used a mice model of prostate cancer, treating mice at distinct stages of the disease and stopping treatment at 28 weeks. When treatment started at eight or 12 weeks, it completely inhibited prostate cancer development and growth. At 22 weeks, researchers found that small cancers had stopped growing and in some cases even regressed.
“Also, to our amazement, while 60 percent of the animals in the control group experienced metastasis to distant organs, none of the treatment group developed metastasis. 4-MU did all of this without causing toxicity to the host,” Travis Yates, former graduate student of the school’s Sheila and David Fuente graduate program in cancer biology, and current postdoctoral fellow at the University of Pennsylvania, said in the news release.
Researchers noted that the earlier the treatment started, the better the protection provided by the 4-MU.
Study funded by NCI.
Physician education is officially beginning and insurance reimbursement will get straightened out. Commercialization is in its infancy. When Afrezza is a two-year-old and walking on its own, things should look a lot different from today.